Pfizer and Valneva Announce Positive Phase 3 VALOR Results
Pfizer and Valneva announced that the Phase 3 VALOR trial of LB6V (PF-07307405) met its primary efficacy endpoint, demonstrating more than 70% efficacy in preventing Lyme disease.
- • 73.2% vaccine efficacy from 28 days post-dose 4
- • 74.8% vaccine efficacy from 1 day post-dose 4
- • No new safety concerns identified — vaccine was well tolerated
- • Pfizer planning regulatory submissions to global health authorities
"These Phase 3 results mark a significant milestone in our shared mission to help prevent Lyme disease."
— Annaliesa Anderson, PhD, Pfizer